The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sanofi Healthcare India Pvt Ltd & PACs

25th September 2026 BSE Limited The National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Dalal Exchange Plaza, C-1, Block G, Bandra-Kurla Street, Mumbai- 400 001 Complex, Bandra (E), Mumbai 400 051 Sanofi India Limited Sanofi House, CTS No. 117-B, L&T Business Park, Saki Vihar Road, Powai, Mumbai 400 072 Dear Sir / Madam, Sub: Disclosure pursuant to Regulation 29(1) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (“SAST Regulations”) This is to inform you that Sanofi Healthcare India Private Limited, an entity part of the promoter group of Sanofi India Limited (“Target Company”) has acquired 3,500,000 equity shares representing 15.20% of the equity share capital of the Target Company from Hoechst GmbH, a promoter of the Target Company. The acquisition has been undertaken pursuant to the exemption available under Regulation 10(1)(a)(iii) of the SAST Regulations, on 24thSeptember 2026 by way of inter se transfer of shares amongst members of the promoter and promoter group of the Target Company through a block deal mechanism on the Stock Exchange. Pursuant to the Regulation 29(1) of the SAST Regulations, please find attached the disclosure in respect of the acquisition of the equity shares of the Target Company. This is for your information and records. Thanking you. Yours faithfully, For Sanofi Healthcare India Private Limited Neha Pokhrana Company Secretary Membership No.: A40082 Encl.: As above Format for disclosures under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 Part-A - Details of the Acquisition Name of the Target Company (TC) Name(s) of the Acquirer and Persons Acting Acquirer: Sanofi Healthcare India Private Limited in Concert (PAC) with the Acquirer PAC: 1.Hoechst GmbH (Seller) 2.SANOFI 3.CKW PHARMA EXTRAKT BETEILIGUNGS UND VERWALTUNGS Gm 4.CKW PHARMA EXTRAKT GMBH & Co.KG 5.Future Capital AG Hessen Life Sciences Chemie 6.Sanofi Aventis de Colombia S.A 7.Sanofi Aventis Deutschland GmbH 8.Starlink Logistics Inc. (SLLI) 9.Aventis Agriculture 10.CARRAIG INSURANCE DAC 11.Sanofi Cathay (Shanghai) Private Equity Investment Fund Partnership (L.P.) 12.Innobio 2 13.Le Rock Re 14.Limited Liability Company Sanofi Aventis Ukraine 15.Sanofi Aventis del Peru S.A 16.Sanofi Aventis Groupe 17.Sanofi Aventis Korea Co., Ltd. 18.Sanofi Aventis Participations 19.Sanofi Aventis Recherche & Développement 20.Sanofi B.V. 21.Cathay Growth (Quanzhou) Equity Investment Fund L.P 22.Sanofi European Treasury Center 23.Sanofi Foreign Participations B.V. 24.SANOFI GESTION SA 25.SANOFI PASTEUR MERIEUX 26.Sanofi R&D Vaccins 27.Sanofi sp. z.o.o. 28.Sanofi (China) Investment Co. Ltd. Whether the Acquirer belongs to Yes, the Acquirer is part of the promoter group of the Target Company. Promoter / Promoter group Name(s) of the Stock Exchange(s) where BSE Limited The National Stock Exchange of India Limited the shares of TC are Listed Details of the acquisition as follows Number % w.r.t. total % w.r.t. total share/voting diluted capital share/voting wherever capital of the applicable (*) TC (**) Before the acquisition under consideration, holding of acquirer along with PAC: a) Shares carrying voting rights - Sanofi Healthcare India Private Nil Nil Nil Limited (Acquirer) - PAC (Composite shareholding of the Promoter and Promoter Group 13,909,587 60.40 60.40 excluding that of the Acquirer- Please refer to the Annexure for a detailed breakdown of the shareholding) b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others) Nil Nil Nil c) Voting rights (VR) otherwise than by equity shares d) Warrants/convertible securities/any Nil Nil Nil other instrument that entitles the acquirer to receive shares carrying Nil Nil Nil voting rights in the TC (specify holding in each category) e) Total (a+b+c+d) 13,909,587 60.40 60.40 Details of acquisition a) Shares carrying voting rights acquired - Sanofi Healthcare India Private 3,500,000 15.20 15.20 Limited (Acquirer) - PAC (Composite shareholding of the Promoter and Promoter Group Nil Nil Nil excluding that of the Acquirer-Please refer to the Annexure for details) b) VRs acquired otherwise than by equity Nil Nil Nil shares c) Warrants/convertible securities/any other instrument that entitles the Nil Nil Nil acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ Nil Nil Nil others) e) Total (a+b+c+d) 3,500,000 15.20 15.20 After the acquisition, holding of acquirer along with PAC: a) Shares carrying voting rights - Sanofi Healthcare India Private 3,500,000 15.20 15.20 Limited (Acquirer) - PAC (Composite shareholding of the Promoter and Promoter Group excluding that of the Acquirer- 10,409,587 45.20 45.20 Please refer to the Annexure for a detailed breakdown of the shareholding) b) VRs otherwise than by equity shares Nil Nil Nil c) Warrants/convertible securities/any other instrument that entitles the Nil Nil Nil acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition d) Shares in the nature of encumbrance Nil Nil Nil (pledge/ lien/ non-disposal undertaking/ others) e) Total (a+b+c+d) 13,909,587 60.40 60.40 Mode of acquisition (e.g. open market / public An inter-se transfer among members of the issue / rights issue / preferential allotment / promoter and promoter group of the Target inter-se transfer / encumbrance, etc.) Company through a block deal mechanism on the Stock Exchange Salient features of the securities acquired Not Applicable including time till redemption, ratio at which it can be converted into equity shares, etc. Date of acquisition of / date of receipt of 24th September 2026 intimation of allotment of shares / VR/ warrants/convertible securities/any other instrument that entitles the acquirer to receive shares in the TC. Equity share capital / total voting capital of the Rs. 230,306,220/- (23,030,622 equity shares of TC before the said acquisition face value of Rs. 10/-) Equity share capital/ total voting capital of the Rs. 230,306,220/- (23,030,622 equity shares of TC after the said acquisition face value of Rs. 10/-) Total diluted share/voting capital of the TC Rs. 230,306,220/- (23,030,622 equity shares of after the said acquisition face value of Rs. 10/-) (*) Total share capital/ voting capital to be taken as per the latest filing done by the Company to the Stock Exchange under Regulation 31 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. (**) Diluted share/voting capital means the total number of shares in the TC assuming full conversionof the outstanding convertible securities/warrants into Equity Shares of the TC. (***) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated. For Sanofi Healthcare India Private Limited Neha Pokhrana Company Secretary Membership No.: A40082 Date: 25th September 2026 Place: Mumbai Annexure: Shareholding of Acquirer and PAC Shareholding details Before the proposed Details of the transaction After the transaction transaction No. of % w.r.t No. of % w.r.t No. of % w.r.t shares total share shares total share shares total capital of capital of share TC TC capital of TC a Acquirer: Sanofi Nil Nil 3,500,000 15.20 3,500,000 15.20 Healthcare India (acquired) (acquired) Private Limited b PAC: 1.Hoechst GmbH 13,904,722 60.38 3,500,000 15.20 10,404,722 45.18 (Seller) (sold) (sold) 2.SANOFI 4,865 0.02 - - 4,865 0.02 3.CKW PHARMA EXTRAKT Nil Nil Nil Nil Nil Nil BETEILIGUNGS UND VERWALTUNGS Gm 4.CKW PHARMA Nil Nil Nil Nil Nil Nil EXTRAKT GMBH & Co.KG 5.Future Capital AG Nil Nil Nil Nil Nil Nil Hessen Life Sciences Chemie 6.Sanofi Aventis de Nil Nil Nil Nil Nil Nil Colombia S.A 7.Sanofi Aventis Nil Nil Nil Nil Nil Nil Deutschland GmbH 8.Starlink Logistics Inc. Nil Nil Nil Nil Nil Nil (SLLI) 9.Aventis Agricultur [Showing first 8,000 characters — download PDF for full document]